Clinical Trial Detail

NCT ID NCT02569476
Title BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications

leukemia

B-cell lymphoma

Therapies

Obinutuzumab + Zanubrutinib

Age Groups: adult senior

No variant requirements are available.